Nasdaq:FDMT

4DMT Reports Full Year 2024 Financial Results, Operational Highlightsand Expected Upcoming Milestones4DMT Reports Full Year 2024 Financial Results, Operational Highlightsand Expected Upcoming Milestones

4DMT Reports Full Year 2024 Financial Results, Operational Highlightsand Expected Upcoming Milestones

February 28, 2025 16:05 ET  | Source: 4D Molecular Therapeutics, Inc. Presented positive interim data through 52 weeks and beyond…

2 weeks ago
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

February 08, 2025 14:30 ET  | Source: 4D Molecular Therapeutics, Inc. 3E10 vg/eye achieved an 83% reduction in injection burden…

1 month ago
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

January 29, 2025 08:00 ET  | Source: 4D Molecular Therapeutics, Inc. Initial interim 52-week results from Phase 2b Population Extension…

2 months ago